0
Specifications:
| Application | Protein Assays & Analysis | ||
| Storage Temperature | –80°C | ||
| Product Type | Recombinant Protein | Forms | Liquid |
| Product Brand | MyBioSource | ||
| Product Grade | Molecular Biology | ||
The SARS-CoV-2 Pseudoviral Particles Spike are replication-deficient MLV pseudotyped viral particles bearing the SARS-CoV-2 spike (S) protein, available in both original D614 (Wuhan-Hu-1) and variant D614G spike forms. These pseudoviruses carry the firefly luciferase reporter gene, enabling quantitative measurement of spike-mediated viral entry into ACE2-expressing cells via luciferase activity.
They are optimized for use in viral entry assays, neutralizing antibody screening, and antiviral drug evaluation, providing a safe, non-replicative alternative to live SARS-CoV-2 for research use.
Key Features
- Robust Signal – High signal-to-noise ratio for sensitive detection.
- Reporter Gene – Firefly luciferase for luminescence-based quantification.
- Safe & Non-Replicative – Pseudotyped MLV particles lacking replication capability.
- High Particle Concentration – >1.0E+07 pseudoviral particles per mL.
- HTS-Compatible – Amenable to 96-, 384-, and 1536-well assay formats.
Applications
- SARS-CoV-2 Entry Assays – Measure spike-mediated entry via ACE2.
- Neutralizing Antibody Screening – Evaluate antibody potency against spike variants.
- Antiviral Drug Testing – Assess compounds that block spike-ACE2 interaction or entry.
- Vaccine Research – Characterize immune response efficacy.
Related Products (Compatible Testing System)
- Negative Control Pseudovirus – MLV-Luciferase without spike (Cat. No. MBS434280)
- ACE2 Stable Cell Line – HEK293-ACE2 (Cat. No. MBS434276)
- Firefly Luciferase Assay Kit – For luminescence readout
Assay Principle
The spike protein binds to the human ACE2 receptor via its receptor-binding domain (RBD) and is activated by host proteases. In this pseudovirus system, successful cell entry results in luciferase expression, quantifiable with a luminescence plate reader.
Example Protocol Overview
- Seed ACE2-expressing target cells (e.g., HEK293-ACE2, Vero E6) in multiwell plates.
- Infect with pseudovirus (thawed quickly at RT, used immediately).
- Incubate for 48 hours (or as per protocol).
- Add luciferase assay working solution directly to wells.
- Read luminescence signal to quantify viral entry.
Neutralization Assay: Pre-incubate pseudovirus with serially diluted antibodies or inhibitors prior to cell infection to assess entry inhibition.
Technical Specifications
| Parameter | Specification |
|---|---|
| Pseudovirus Backbone | MLV (murine leukemia virus) |
| Reporter | Firefly luciferase |
| Particle Concentration | >1.0E+07 particles/mL |
| Volume | 5 mL (1 mL/tube) |
| Format | Frozen, shipped on dry ice |
| Storage | –70°C; stable for 6 months |
| Assay Format Compatibility | 96-, 384-, 1536-well plates |
| Biosafety Level | BSL-2 recommended |
| Research Use | For research use only |
The SARS-CoV-2 Pseudoviral Particles Spike offer a highly reliable, safe, and quantifiable platform for studying SARS-CoV-2 entry mechanisms, evaluating neutralizing antibodies, and screening antiviral agents. With luciferase-based detection and compatibility with high-throughput screening systems, these pseudoviruses are an essential research tool for COVID-19 virology and therapeutic development.
- Pack Size: 1 x 5 mL 5 x 1mL